Market Overview:
The global trial size antibodies market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for monoclonal antibodies and polyclonal antibodies from hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, research institutes, and others. Additionally, the growing focus on personalized medicine is also contributing to the growth of this market. North America dominates the global trial size antibodies market followed by Europe and Asia Pacific.
Product Definition:
Trial size antibodies are used to determine the efficacy of a therapeutic antibody. They are used to test whether an antibody can bind to its target and block it from functioning. This is done by attaching a fluorescent molecule to the antibody, which will allow scientists to track its movement in the body. If an antibody can successfully attach itself to its target and block it from functioning, then it may be developed into a therapeutic drug.
Monoclonal:
Monoclonal antibodies (mAbs) are antibody molecules, which are produced by the body's immune system. The most common mAbs found in humans are those that attach themselves to cancer cells and kill them. Monoclonal antibodies can be used for the diagnosis of diseases as well as for therapeutic purposes.
Polyclonal:
Polyclonal antibodies are made by the B cell and they are directed against a specific antigen. These antibodies can recognize multiple antigens on one epitope. They have higher affinity for the antigen than monoclonal antibody but lower than polyclonal antibody.
The advantages of using polyclonal antibodies in research include that it is relatively easy to make, it does not require skilled professionals,.
Application Insights:
The hospitals & diagnostic laboratories segment dominated the global trial size antibodies market in 2017. This is attributed to factors such as an increase in cancer cases and a rise in demand for rapid, accurate and sensitive molecular diagnostic tests for cancer. In addition, an increase in spending on R&D pertaining to the development of novel drugs is expected to boost product demand over the forecast period.
Pharmaceutical & biotechnology companies are involved heavily in research & development activities pertaining to antibody products that can be used across various therapeutic areas, such as oncology, infectious diseases and autoimmune disorders. The presence of a strong pipeline coupled with increasing investment by pharmaceutical companies has fueled segment growth over the past few years.
Regional Analysis:
North America dominated the global trial size antibodies market in 2017. The presence of well-established healthcare infrastructure, high per capita income and prevalence of chronic diseases are some factors responsible for its large share. In addition, increasing government funding for R&D is also expected to propel the region’s growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising investments by foreign players in this region along with growing awareness about new treatment options and availability of effective therapies among patients and physicians.
Major companies include but are not limited to AbbVie Inc.; CSL Limited; FUJIFILM Diosynth Biotechnologies ULC; Novartis AG; Pfizer Inc.; Roche Holding Ltd.
Growth Factors:
- Increasing demand for personalized medicine
- Growing prevalence of target diseases
- Technological advancements in antibody discovery and production processes
- Rising number of clinical trials
- Increasing investment in R&D
Scope Of The Report
Report Attributes
Report Details
Report Title
Trial Size Antibodies Market Research Report
By Type
Monoclonal, Polyclonal
By Application
Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology, Research Institutes, Others
By Companies
Agrisera, Bio-Rad, Biorbyt, BioVision, BosterBio, Diagenode, EpiGentek, GeneTex, MBL International, Novus Biologicals, R&D Systems
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
180
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Trial Size Antibodies Market Report Segments:
The global Trial Size Antibodies market is segmented on the basis of:
Types
Monoclonal, Polyclonal
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology, Research Institutes, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Agrisera
- Bio-Rad
- Biorbyt
- BioVision
- BosterBio
- Diagenode
- EpiGentek
- GeneTex
- MBL International
- Novus Biologicals
- R&D Systems
Highlights of The Trial Size Antibodies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal
- Polyclonal
- By Application:
- Hospitals & Diagnostic Laboratories
- Pharmaceutical & Biotechnology
- Research Institutes
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Trial Size Antibodies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Trial size antibodies are small quantities of antibody that have been produced in a laboratory for research purposes.
Some of the major players in the trial size antibodies market are Agrisera, Bio-Rad, Biorbyt, BioVision, BosterBio, Diagenode, EpiGentek, GeneTex, MBL International, Novus Biologicals, R&D Systems.
The trial size antibodies market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Trial Size Antibodies Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Trial Size Antibodies Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Trial Size Antibodies Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Trial Size Antibodies Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Trial Size Antibodies Market Size & Forecast, 2020-2028 4.5.1 Trial Size Antibodies Market Size and Y-o-Y Growth 4.5.2 Trial Size Antibodies Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Monoclonal
5.2.2 Polyclonal
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals & Diagnostic Laboratories
6.2.2 Pharmaceutical & Biotechnology
6.2.3 Research Institutes
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Trial Size Antibodies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Trial Size Antibodies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Monoclonal
9.6.2 Polyclonal
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals & Diagnostic Laboratories
9.10.2 Pharmaceutical & Biotechnology
9.10.3 Research Institutes
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Monoclonal
10.6.2 Polyclonal
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals & Diagnostic Laboratories
10.10.2 Pharmaceutical & Biotechnology
10.10.3 Research Institutes
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Monoclonal
11.6.2 Polyclonal
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals & Diagnostic Laboratories
11.10.2 Pharmaceutical & Biotechnology
11.10.3 Research Institutes
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Monoclonal
12.6.2 Polyclonal
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals & Diagnostic Laboratories
12.10.2 Pharmaceutical & Biotechnology
12.10.3 Research Institutes
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Monoclonal
13.6.2 Polyclonal
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals & Diagnostic Laboratories
13.10.2 Pharmaceutical & Biotechnology
13.10.3 Research Institutes
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Trial Size Antibodies Market: Competitive Dashboard
14.2 Global Trial Size Antibodies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Agrisera
14.3.2 Bio-Rad
14.3.3 Biorbyt
14.3.4 BioVision
14.3.5 BosterBio
14.3.6 Diagenode
14.3.7 EpiGentek
14.3.8 GeneTex
14.3.9 MBL International
14.3.10 Novus Biologicals
14.3.11 R&D Systems